Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

BioNexus Gene Lab (BGLC) Gross Profit (2018 - 2025)

Historic Gross Profit for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $377685.0.

  • BioNexus Gene Lab's Gross Profit rose 1566.41% to $377685.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 1215.81%. This contributed to the annual value of $1.3 million for FY2024, which is 300.69% down from last year.
  • BioNexus Gene Lab's Gross Profit amounted to $377685.0 in Q3 2025, which was up 1566.41% from $368022.0 recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Gross Profit high stood at $709194.0 for Q3 2021, and its period low was $263971.0 during Q2 2022.
  • Over the past 5 years, BioNexus Gene Lab's median Gross Profit value was $354332.0 (recorded in 2023), while the average stood at $379146.4.
  • In the last 5 years, BioNexus Gene Lab's Gross Profit surged by 19355.7% in 2021 and then tumbled by 5776.91% in 2022.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Gross Profit stood at $477167.0 in 2021, then fell by 28.91% to $339226.0 in 2022, then decreased by 21.42% to $266555.0 in 2023, then increased by 16.01% to $309234.0 in 2024, then rose by 22.14% to $377685.0 in 2025.
  • Its last three reported values are $377685.0 in Q3 2025, $368022.0 for Q2 2025, and $343493.0 during Q1 2025.